Co-Diagnostics (HAM:C970) Total Stockholders Equity: €13.88 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:C970 Co-Diagnostics Inc HAM:C970
61 GF Score
Price €5.55
GF Value €8.33
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Total Stockholders Equity?

Co-Diagnostics HAM:C970 61 Total Stockholders Equity is €13.88 Mil as of Mar. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 61/100 and a GF Value™ of €8.33. The stock has 6 warning signs investors should review.

Co-Diagnostics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €13.88 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Co-Diagnostics's Book Value per Share for the quarter that ended in Mar. 2026 was €3.85. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Co-Diagnostics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.13.

Co-Diagnostics  (HAM:C970) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Co-Diagnostics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(13.876-0)/3.602
=3.85

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Co-Diagnostics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.742 + 1.015) / 13.876
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Total Stockholders Equity Related Terms

Co-Diagnostics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Total Stockholders Equity Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 119.01 108.11 78.88 51.45 17.62

Co-Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.67 33.93 17.62 13.88 11.03
HAM:C970
61GF Score
Co-Diagnostics Inc HAM:C970
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €13.88 Mil mean?
Co-Diagnostics (HAM:C970) has a Total Stockholders Equity of €13.88 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Co-Diagnostics and its competitors.
Is Co-Diagnostics' Total Stockholders Equity too high?
Co-Diagnostics' current Total Stockholders Equity is €13.88 Mil. Overall, Co-Diagnostics has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Total Stockholders Equity compare to HSCS and NVNO?
Co-Diagnostics' Total Stockholders Equity of €13.88 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Co-Diagnostics and its competitors. Co-Diagnostics's current Total Stockholders Equity is €13.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Total Stockholders Equity of €13.88 Mil. The stock's GF Value™ is €8.33, compared to a current price of €5.55 — trading 33.4% below its estimated fair value. The current Total Stockholders Equity is €13.88 Mil. Co-Diagnostics' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Total Stockholders Equity is €13.88 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of €5.55 is trading 33.4% below its estimated GF Value™ of €8.33.

Key valuation signals for HAM:C970:

  • Total Stockholders Equity: €13.88 Mil
  • GF Value™: €8.33 vs. price of €5.55 (33.4% below fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
61GF Score

Get the complete analysis for HAM:C970

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€8.33
GF Value